Kyongbo Pharmaceutical KRX:214390KOSPI
경보제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked1since Sep 11
In Q2 2026, Kyongbo Pharmaceutical reported revenue of ₩75.2bn, up 15.2% year on year, and operating profit of ₩930m. Kyongbo Pharmaceutical (경보제약) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Kyongbo Pharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩75.2bn | +15.2% | ₩930m margin 1.2% | ₩3.0bn |
| Q1 2026 | ₩66.1bn | +9.1% | ₩713m margin 1.1% | −₩530m |
| Q4 2025 derived | ₩71.2bn | +20.1% | ₩516m margin 0.7% | −₩433m |
| Q3 2025 | ₩67.0bn | +15.0% | ₩474m margin 0.7% | ₩3.0bn |
| Q2 2025 | ₩65.3bn | +11.8% | ₩2.4bn margin 3.7% | −₩1.7bn |
| Q1 2025 | ₩60.6bn | -3.2% | ₩121m margin 0.2% | −₩695m |
| Q4 2024 derived | ₩59.3bn | -3.2% | ₩3.0bn margin 5.0% | ₩1.8bn |
| Q3 2024 | ₩58.2bn | +6.7% | ₩3.2bn margin 5.4% | ₩1.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Kyongbo Pharmaceutical top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.